Ladenburg analyst Matthew Kaplan raised the firm’s price target on Ardelyx to $8.50 from $7.50 and keeps a Buy rating on the shares following the “robust” Q2 results. The firm continues to be impressed with the launch of Ibsrela.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- Ardelyx sees FY23 IBSRELA net sales revenue $72M-$77M
- Ardelyx reports Q2 EPS (8c), consensus (11c)
- Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
- Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
- Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference